Anne Wojcicki, 23andMe CEO (Jordan Vonderhaar/Bloomberg via Getty Images)

23andMe to shut down its ther­a­peu­tics di­vi­sion

23andMe is clos­ing its ther­a­peu­tics di­vi­sion and will wind down on­go­ing clin­i­cal tri­als, the strug­gling ge­net­ic test­ing com­pa­ny said Mon­day evening.

The com­pa­ny said it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.